VALIDATION OF (-)-N-3-BENZYL-PHENOBARBITAL AS A SELECTIVE INHIBITOR OF CYP2C19 IN HUMAN LIVER MICROSOMES
Open Access
- 20 May 2004
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET)
- Vol. 32 (6), 584-586
- https://doi.org/10.1124/dmd.32.6.584
Abstract
(-)-N-3-Benzyl-phenobarbital (NBPB) was reported to be a potent and selective inhibitor of CYP2C19. To validate the selectivity of NBPB toward CYP2C19 in human liver microsomes, the inhibitory effects on major cytochrome P450 isoform-specific reactions were evaluated in the present study. In human liver microsomes, NBPB showed potent competitive inhibition on CYP2C19-mediated S-mephenytoin 4′-hydroxylation with an IC50 value of 0.25 μM and Ki value of 0.12 μM, whereas weak inhibition was observed for CYP1A2-, CYP2A6-, CYP2B6-, CYP2C8-, CYP2C9-, CYP2D6-, and CYP3A4-mediated reactions with IC50 values >100, >100, 62, 34, 19, >100, and 89 μM, respectively. Importantly, its selectivity toward CYP2C19 among the CYP2C subfamily was demonstrated. Therefore, NBPB can be used as a potent and selective inhibitor to establish the relative contribution of CYP2C19 for in vitro reaction phenotyping studies. This compound can also serve as a positive control inhibitor of CYP2C19 for routine screening of P450 reversible inhibition when human liver microsomes are used as the enzyme source.Keywords
This publication has 19 references indexed in Scilit:
- THE CONDUCT OF IN VITRO AND IN VIVO DRUG-DRUG INTERACTION STUDIES: A PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PhRMA) PERSPECTIVEPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2003
- Cytochrome P450 Phenotyping/Genotyping in Patients Receiving AntipsychoticsClinical Pharmacokinetics, 2002
- Clinical relevance of genetic polymorphisms in the human CYP2C subfamilyBritish Journal of Clinical Pharmacology, 2001
- Ticlopidine as a Selective Mechanism-Based Inhibitor of Human Cytochrome P450 2C19Biochemistry, 2001
- In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6British Journal of Clinical Pharmacology, 2000
- DiscussionBiochemical Pharmacology, 1999
- Inhibition and Induction of Cytochrome P450 and the Clinical ImplicationsClinical Pharmacokinetics, 1998
- Evidence That CYP2C19 is the Major (S)-Mephenytoin 4'-Hydroxylase in HumansBiochemistry, 1994
- Isolation and Characterization of Human Liver Cytochrome P450 2C19: Correlation between 2C19 and S-Mephenytoin 4′-HydroxylationArchives of Biochemistry and Biophysics, 1993
- In Vitro Methods for Assessing Human Hepatic Drug Metabolism: Their use in Drug DevelopmentDrug Metabolism Reviews, 1993